Development of a novel tyrosine kinase 2 inhibitor ARTS‐011 and its first‐in‐human single and multiple ascending dose Phase I study to evaluate the tolerability, safety, pharmacokinetic profile and food effects

Similar Items

• Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies
  by: Yuji Kumagai, et al.
  Published: (2025)
• Evaluation of drug–drug interactions of a novel potent FLT3 inhibitor SKLB1028 in healthy subjects
  by: Jingcheng Chen, et al.
  Published: (2024)
• Single‐ascending dose and food effect studies to assess safety and pharmacokinetics of ainuovirine, a novel non‐nucleoside reverse transcriptase inhibitor, for treatment of HIV‐1 infection
  Published: (2024)
• Efficacy, tolerability, and safety of Efsubaglutide Alfa in participants with obesity or overweight ( LIGHT 1): A randomized, double‐blind, placebo‐controlled, ascending‐dose phase 2a trial
  by: Fei Gao, et al.
  Published: (2026)
• Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase‐1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose study
  by: Yuhao Wang, et al.
  Published: (2025)